What Is the Role of Nanotechnology in Diagnosis and Treatment of Metastatic Breast Cancer? Promising Scenarios for the Near Future

Truffi, Marta; Sorrentino, Luca; Mazzucchelli, Serena; Fiandra, Luisa; Corsi, Fabio

doi:10.1155/2016/5436458

Cited by 17 publications

(5 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metastasis is a sequential process that allows cancer cells to move from the primary tumor site and grow elsewhere in the human body [5,24]. This is still the leading cause of death in patients with breast cancer [25,26].…”

Section: Discussionmentioning

confidence: 99%

Nilotinib, a Discoidin domain receptor 1 (DDR1) inhibitor, induces apoptosis and inhibits migration in breast cancer

Wang¹,

Xie²,

Bao³

et al. 2021

neo

View full text Add to dashboard Cite

Overexpression of Discoidin domain receptor 1 (DDR1) is known to enhance the malignancy of breast cancer considerably. This study reports the identification of a potent DDR1 inhibitor, Nilotinib, for the treatment of breast cancer. MTT assay was used to evaluate the inhibitory activity of Nilotinib and meantime we used flow cytometry to evaluate the pro-apoptotic activity of Nilotinib against MCF-7 and MDA-MB-231. Expression of DDR1 was manipulated in MDA-MB-231 and MCF-7 cell lines with low-level DDR1 expression by transfecting with plasmids containing shRNA. The effect of DDR1 or treatment with Nilotinib on cell migration was assayed. The expression of p-DDR1, DDR1, p-ERK1/2, ERK1/2 and E-cadherin, Vimentin, Snail1, and caspase 3 were detected by western blot and immunofluorescent staining. Nilotinib against MCF-7 -MBapoptotic cell death. After co-culturing with Nilotinib (500 nM), apoptosis rate is 29.60 % ± 2.19% and 18.75 % ± 2.30%, respectively. Moreover, Nilotinib effectually blocked the cellular migration of MCF-7. Interestingly, the knock-down DDR1 could significantly block the migration of breast cancer, meantime the sensitivity of MCF-7 and MDA-MB-231 to Nilotinib was reduced. Targeting DDR1 therapeutically could potentially affect survival and influence metabolism in breast cancer, and Nilotinib could be used as a candidate for the treatment of breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Nilotinib, a Discoidin domain receptor 1 (DDR1) inhibitor, induces apoptosis and inhibits migration in breast cancer

Wang¹,

Xie²,

Bao³

et al. 2021

neo

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Recent reports have revealed that breast cancer is responsible for 6% of the total 7.5 million cancer mortalities worldwide [3,4]. Although numerous advanced diagnostic and therapeutic methods have been used in the treatment of breast cancer, but its metastasis is still the primary cause of death [5,6].…”

Section: Introductionmentioning

confidence: 99%

Nilotinib, a Discoidin domain receptor 1 (DDR1) inhibitor, induces apoptosis and inhibits migration in breast cancer

Wang

Xie

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Overexpression of Discoidin domain receptor 1(DDR1) is known to enhance the malignancy of breast cancer considerably. This study reports the identification of a potent DDR1 inhibitor, Nilotinib for the treatment of breast cancer. Methods: MTT assay was used to evaluate the inhibitory activity of Nilotinib and meantime we used flow cytometry to evaluate the pro-apoptotic activity of Nilotinib against MCF-7 and MDA-MB-231. Expression of DDR1 was manipulated in MCF-7 cell lines with low level DDR1 expression by transfecting with plasmids containing by shRNA. The effect of DDR1 or treatment with Nilotinib on cell migration was assayed. The expression of p-DDR1, DDR1, p-ERK1/2, ERK1/2 and E-cadherin，Vimentin, Snail1 were detected by western blot and immuno-fluorescent staining.Results: Nilotinib against MCF-7 (IC50=0.403 μM) and MDA-MB-231 (IC50=0.819 μM) and also indicated induced apoptotic cell death after co-cuturing with Nilotinib (500 nM), apoptosis rate is 29.60 % ± 2.19% and 18.75 % ± 2.30% respectively. Moreover, Nilotinib effectually blocked cellular migration of MCF-7. Interestingly, Knock-down DDR1 could significantly block the migration of breast cancer, meantime the sensitivity of MCF-7 to Nilotinib was reduced.Conclusion: Targeting DDR1 therapeutically could potentially affect survival and influence metabolism in breast cancer, and Nilotinib could as a candidate for the treatment of breast cancer.

show abstract

“…Metastasis is a sequential process that allows cancer cells to move from the primary tumor site and grow elsewhere in the human body [5,23]. This is still the leading cause of death in patients with breast cancer [24,25].…”

Section: Discussionmentioning

confidence: 99%

Nilotinib, a Discoidin domain receptor 1 (DDR1) inhibitor, induces apoptosis and inhibits migration in breast cancer

Wang

Xie

et al. 2019

Preprint

View full text Add to dashboard Cite

Background: Overexpression of Discoidin domain receptor 1(DDR1) is known to enhance the malignancy of breast cancer considerably. This study reports the identification of a potent DDR1 inhibitor, Nilotinib for the treatment of breast cancer. Methods: MTT assay was used to evaluate the inhibitory activity of Nilotinib and meantime we used flow cytometry to evaluate the pro-apoptotic activity of Nilotinib against MCF-7 and MDA-MB-231. Expression of DDR1 was manipulated in MCF-7 cell lines with low level DDR1 expression by transfecting with plasmids containing by shRNA. The effect of DDR1 or treatment with Nilotinib on cell migration was assayed. The expression of p-DDR1, DDR1, p-ERK1/2, ERK1/2 and E-cadherin，Vimentin, Snail1 were detected by western blot and immuno-fluorescent staining . Results: Nilotinib against MCF-7 (IC 50 =0.403 μM) and MDA-MB-231 (IC 50 =0.819 μM) and also indicated induced apoptotic cell death after co-cuturing with Nilotinib (500 nM), apoptosis rate is 29.60 % ± 2.19% and 18.75 % ± 2.30% respective ly. Moreover, Nilotinib effectually blocked cellular migration of MCF-7. Interestingly, Knock-down DDR1 could significantly block the migration of breast cancer, meantime the sensitivity of Nilotinib to MCF-7 was reduced. Conclusion: Targeting DDR1 therapeutically could potentially affect survival and influence metabolism in breast cancer, and Nilotinib could as a candidate for the treatment of breast cancer.

show abstract

What Is the Role of Nanotechnology in Diagnosis and Treatment of Metastatic Breast Cancer? Promising Scenarios for the Near Future

Cited by 17 publications

References 112 publications

Nilotinib, a Discoidin domain receptor 1 (DDR1) inhibitor, induces apoptosis and inhibits migration in breast cancer

Nilotinib, a Discoidin domain receptor 1 (DDR1) inhibitor, induces apoptosis and inhibits migration in breast cancer

Nilotinib, a Discoidin domain receptor 1 (DDR1) inhibitor, induces apoptosis and inhibits migration in breast cancer

Nilotinib, a Discoidin domain receptor 1 (DDR1) inhibitor, induces apoptosis and inhibits migration in breast cancer

Contact Info

Product

Resources

About